Ethylene-Vinyl Alcohol Copolymer Dialyzer Membrane Reduces Protein Oxidation in Hemodialysis Patients

Figures & data

Table 1.  Clinical characteristics and baseline laboratory values in patients recruited in the first and second studies

Measurement	1st study HNA/AOPP	2nd study MPO
Male/Female	7/3	6/6
Age years	72.9 ± 7.8	74.4 ± 7.0
Duration on dialysis years	4.2 ± 2.3	6.7 ± 3.9
Primary causes of ESRD
Diabetes	4	5
Hypertension	3	3
Glomerulonephritis	1	3
Others	2	1
Albumin (g/dL)	3.8 ± 0.3	3.9 ± 0.2
Total protein (g/dL)	6.4 ± 0.3	6.6 ± 0.4
Hemoglobin (g/dL)	10.7 ± 1.4	10.1 ± 0.8
Creatinine levels (mg/dL)	11.8 ± 1.1	9.5 ± 1.5
Urea levels (mg/dL)	68.7 ± 9.2	62.4 ± 17.8
Urea reduction ratio %	71.4 ± 3.7	73.7 ± 2.8

Notes: Continuous variables are expressed as mean values ± SD.

HNA, nonmercaptalbumin; AOPP, advanced oxidation protein products; MPO, myeloperoxidase; ESRD, end-stage renal disease.

Figure 1. Plasma predialysis HNA proportions during EVAL and CTA treatments. HNA indicates HNA-1 + HNA-2. Plasma HNA proportions showed no obvious difference between the baseline, after EVAL treatment, and after CTA treatment.

Figure 2. Changes in predialysis AOPP levels during EVAL and CTA treatments. The plasma levels of AOPP decreased after 2 months of EVAL treatment and then increased again after the following 2 months of CTA treatment. Data are presented as mean ± SD.

Figure 3. Effects of 2 weeks of EVAL treatment on predialysis MPO levels. The plasma MPO levels immediately before HD significantly decreased after 2 weeks of EVAL treatment.